Fri.Apr 12, 2024

article thumbnail

With 9% pay hike, Merck CEO Davis entered $20M compensation club in 2023

Fierce Pharma

Merck CEO Robert Davis has cracked the $20-million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters. | Merck CEO Robert Davis has cracked the $20-million mark in annual pay for the first time, putting him in an exclusive club of biopharma heavy hitters. Davis, 57, received a 9% bump in pay in 2023 to $20.3 million, according to the company’s proxy filing.

Biopharma 293
article thumbnail

Why Hospitals Are Condemning CMS’ Proposed Inpatient Payment Rule

MedCity News

CMS released a proposed rule this week that would boost hospitals’ inpatient payment rates by 2.6%. Hospitals groups have swiftly denounced this plan, arguing that this payment update is insufficient and will jeopardize hospitals’ financial stability. The post Why Hospitals Are Condemning CMS’ Proposed Inpatient Payment Rule appeared first on MedCity News.

126
126
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Shareholders approve AstraZeneca's 2024 pay proposal for CEO Pascal Soriot despite proxy adviser discontent

Fierce Pharma

History is repeating for AstraZeneca CEO Pascal Soriot, who successfully dodged an executive pay revolt at the company’s annual meeting Thursday, echoing a similar situation that played out in 2021 | Out of more than 1.18 billion votes cast by AstraZeneca shareholders at the company's annual meeting this week, 64.43% of investors voted in favor of an updated pay policy that could see CEO Pascal Soriot earn upward of 18.7 million pounds sterling ($23.5 million) for his performance this year.

290
290
article thumbnail

Study suggests tumour microenvironments could predict cancer progression

PharmaTimes

NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases

126
126
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

FDA advisers back new endpoint for myeloma approvals, paving way for faster introduction of new drugs

Fierce Pharma

After oncology experts reviewed arguments in favor of a surrogate endpoint to support multiple myeloma drug approvals, drug developers may soon have a new pathway in the R&D journey. | After oncology experts reviewed arguments in favor of a surrogate endpoint to support multiple myeloma drug approvals, drug developers may soon have a new pathway in the R&D journey.

FDA 279
article thumbnail

Bridging the Gap Between Physical and Mental Health

MedCity News

Prioritizing integration and accessibility is not just good practice, it’s a moral and strategic imperative. The post Bridging the Gap Between Physical and Mental Health appeared first on MedCity News.

119
119

More Trending

article thumbnail

Kaiser Permanente Unveils Food is Medicine Center of Excellence

MedCity News

Kaiser Permanente’s new Food is Medicine Center of Excellence will “combine clinical services, research, education and community engagement,” according to the organization. The post Kaiser Permanente Unveils Food is Medicine Center of Excellence appeared first on MedCity News.

Food 119
article thumbnail

EMA Says No Evidence for Link between Type 2 Diabetes Drugs and Suicidal Tendencies

PharmaTech

The agency’s risk assessment committee has concluded that available evidence has not been found that supports a causal association between glucagon-like peptide-1 receptor agonists and self-harming thoughts and actions.

119
119
article thumbnail

BioMarin’s Voxzogo shows promise in hypochondroplasia

pharmaphorum

BioMarin’s Voxzogo has been shown to increase growth rates in children with hypochondroplasia, a genetic cause of very short stature, in a phase 2 trial

111
111
article thumbnail

Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials

MedCity News

Torl BioTherapeutics’ $158 million Series B-2 financing will finance clinical testing of its pipeline of antibody drug conjugates in development for various types of cancer. Neuroscience and immunology are among the therapeutic areas represented in our roundup of other recent biotech financings. The post Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials appeared first on MedCity News.

Biopharma 105
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

TORL rakes in $158m for ADCs, and other bio financings

pharmaphorum

Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics.

110
110
article thumbnail

CRISPR technologies fuelling haematological innovations

European Pharmaceutical Review

There has been a “notable” rise in licensing agreements for innovator drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology for gene therapies over the past five years, according to data and analytics firm GlobalData. These agreements have amassed a total deal value of $21 billion. Of note, between 2020 to 2022, there was a “remarkable surge” in deal worth.

article thumbnail

Ex-broadcaster Paxman hands Parkinson’s wish list to UK PM

pharmaphorum

To mark World Parkinson’s Day, former broadcaster Jeremy Paxman has delivered a list of recommendations for improving how the disease is managed in the UK to Prime Minister Rishi Sunak.

article thumbnail

Pharma Pulse 4/12/24: The Road Ahead for GenAI-Enabled/Augmented Clinical Trials, The Health and Healthcare of Boomers & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 102
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

AZ shareholders back CEO Soriot’s pay package, amid dissent

pharmaphorum

Shareholders in AstraZeneca have voted to approve controversial increase in the salary and bonus package for CEO Pascal Soriot.

104
104
article thumbnail

Moderna pauses plans to build mRNA facility in Kenya

Pharmaceutical Technology

Moderna has announced the halt of its project to build a messenger ribonucleic acid (mRNA) manufacturing facility in Kenya.

article thumbnail

3 big recent trial flops

PharmaVoice

Why these clinical setbacks impacted the companies, industry and patients.

article thumbnail

Novel medicine could address short stature in children

European Pharmaceutical Review

The first-of-its-kind global Phase II study for vosoritide has demonstrated that children with hypochondroplasia, a genetic cause of short stature in children, achieved an increased average growth rate of 1.8 cm annually. [vosoritide] is the first medicine that has been developed to specifically target the pathway involved in hypochondroplasia” “This is the first medicine that has been developed to specifically target the pathway involved in hypochondroplasia,” commented Dr Andrew Dauber,

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

KCL and McMaster University partner to advance nuclear medicine research

PharmaTimes

Both partners’ will leverage their nuclear research facilities and expertise to develop new health interventions

article thumbnail

UK charities condemn continued drug shortages

Pharmaceutical Technology

As the UK tackles several drug shortages, UK charities and pharmacists called for urgent action to be taken.

78
article thumbnail

Does the Use of Hepatitis C Antivirals Surge Following an Easing of Medicaid Coverage Restrictions?

Pharmaceutical Commerce

A difference-in-differences analysis explores the correlation between direct-acting antiviral prescriptions for hepatitis C virus and the softening of state-level limitations.

article thumbnail

Selling A Life Saving App With Military Veteran Bryan Lorden

Evolve Your Success

When Bryan Lorden’s life was touched by tragedy, it sparked a mission: to prevent others from experiencing the same heartache. That’s what led Bryan, a military veteran, to create Vesta Sleep, a life-saving app we dive into in our latest episode. This innovative tool, designed for wearable tech, doesn’t just track sleep—it also has the potential to alert users and their emergency contacts during critical medical situations, a feature born from the devastating loss of Bryan

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Novartis, Arvinas Agree to Strategic Collaboration to Develop Treatment for Prostate Cancer

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

FDA approves new administration routes for Xcopri 

Pharmaceutical Technology

SK Life Sciences Xcopri (cenobamate) is approved as an oral suspension mixed with water for mouth administration or via a nasogastric tube.

FDA 52
article thumbnail

Latent Benefit of Access Restrictions for Rare Conditions

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

Century secures $60m in stock sale and buys preclinical cell therapy biotech

Pharmaceutical Technology

Century Therapeutics will pay $35m upfront and an additional $10m milestone payments to acquire Clade Therapeutics.

Sales 52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Novartis Initiates Voluntary Public Takeover of MorphoSys AG

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

Candel wins FDA orphan drug designation for pancreatic cancer drug

Pharmaceutical Technology

The FDA designation follows positive Phase II data announced recently.

FDA 52
article thumbnail

Supply Shortages in Weight Loss Drugs

PharmExec

In this Pharmaceutical Executive video interview, Currax Pharmaceuticals, CEO, George Hampton, discusses factors that are contributing to ongoing supply issues and if prices for these therapies are coming down anytime soon.

article thumbnail

Mitigating Drug Shortages

Pharmaceutical Commerce

Allen Jacques explains the history behind medications’ lack of supply, while offering ways to help alleviate their impact.

Medical 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A